Ipamorelin

Ipamorelin is a pentapeptide and selective growth hormone secretagogue (GHS) that acts as an agonist at the ghrelin receptor. Unlike other GH secretagogues, ipamorelin is highly selective for GH release and does not significantly increase cortisol or prolactin. It has been studied in clinical trials for growth hormone deficiency and postoperative ileus.

PubMed results: 44 · Human studies: 19 · Animal studies: 39

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

Based on clinical trial data and published studies

• Subcutaneous Injection — standard range 200-300 mcg, 2-3 times daily. 8-12 weeks

~2 hours (moderate confidence)

• Growth hormone release (Human clinical data): Selective GH stimulation without cortisol or prolactin elevation

• Headache — Mild, Uncommon

• Active malignancy / GH–IGF-1 axis concerns (Theoretical / Preclinical): As a selective ghrelin-receptor GHS that elevates growth hormone, ipamorelin raises theoretical concern in active cancer research settings where GH/IGF-1 pathway stimulation is undesirable
• Uncontrolled diabetes or significant insulin resistance research cautions (Theoretical / Preclinical): Growth hormone elevation can antagonize insulin action; GHS peptides including ipamorelin are studied cautiously when glycemic endpoints or uncontrolled hyperglycemia are primary concerns

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water

• NCT01280344 — Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function (PHASE2), status: COMPLETED. Indications: Gastrointestinal Dysmotility
• NCT00672074 — Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus (PHASE2), status: COMPLETED. Indications: Ileus

Aib-His-D-2-Nal-D-Phe-Lys-NH2